Top 16 Monoclonal Antibody startups
Nov 16, 2025
Like
15
These startups focus on creating highly specific antibodies that can bind to unique antigens on diseased cells, offering more effective treatment options with fewer side effects compared to traditional therapies.
1
Country: Switzerland | Funding: $1B
ADC Therapeutics is focused on the creation of proprietary Antibody Drug Conjugates (ADCs) for the therapy of both solid and hematological cancers. It uses monoclonal antibodies specific to specific tumor antigens conjugated to a innovative class of highly potent pyrrolobenzodiazepine (PBD)-based warheads to specifically kill cancer cells. The company is expanding ZYNLONTA into earlier stages of DLBCL and indolent lymphomas. In addition, IND-enabling efforts are in progress for the Company’s exatecan-based, prostate-specific membrane antigen.
ADC Therapeutics is focused on the creation of proprietary Antibody Drug Conjugates (ADCs) for the therapy of both solid and hematological cancers. It uses monoclonal antibodies specific to specific tumor antigens conjugated to a innovative class of highly potent pyrrolobenzodiazepine (PBD)-based warheads to specifically kill cancer cells. The company is expanding ZYNLONTA into earlier stages of DLBCL and indolent lymphomas. In addition, IND-enabling efforts are in progress for the Company’s exatecan-based, prostate-specific membrane antigen.
2
Country: Belgium | Funding: $325.6M
AgomAb Therapeutics is a Company is developing growth factor-mimetic agonistic monoclonal antibodies to regenerate damaged tissues.
AgomAb Therapeutics is a Company is developing growth factor-mimetic agonistic monoclonal antibodies to regenerate damaged tissues.
3
Country: USA | Funding: $513M
Zenas BioPharma is a biopharmaceutical company that focuses on developing immune-based therapies for patients.
Zenas BioPharma is a biopharmaceutical company that focuses on developing immune-based therapies for patients.
4
Country: USA | Funding: $496M
Invivyd develops antibodies to transcend the limitations of the human immune system and fight against viral infections.
Invivyd develops antibodies to transcend the limitations of the human immune system and fight against viral infections.
5
Country: Ireland | Funding: $245.9M
SynOx is developing emactuzumab, a best-in-class CSF1R targeted therapeutic antibody designed to target and deplete tumour-associated macrophages in the tumour tissue.
SynOx is developing emactuzumab, a best-in-class CSF1R targeted therapeutic antibody designed to target and deplete tumour-associated macrophages in the tumour tissue.
6
Country: USA | Funding: $1.4B
ImmunityBio is a privately held immunotherapy company with one of the broadest portfolios of biological molecules spanning albumin-linked chemotherapeutic, peptides, fusion proteins, cytokine, monoclonal antibodies, adenovirus and yeast vaccine therapies.
ImmunityBio is a privately held immunotherapy company with one of the broadest portfolios of biological molecules spanning albumin-linked chemotherapeutic, peptides, fusion proteins, cytokine, monoclonal antibodies, adenovirus and yeast vaccine therapies.
7
Country: USA | Funding: $1.3B
Arcus discovers and develops innovative cancer immunotherapies based on known but under-exploited biology. Arcus’s lead program targets the adenosine pathway, which has been shown to play a significant role in driving immuno-suppression in the tumor micro-environment.
Arcus discovers and develops innovative cancer immunotherapies based on known but under-exploited biology. Arcus’s lead program targets the adenosine pathway, which has been shown to play a significant role in driving immuno-suppression in the tumor micro-environment.
8
Country: USA | Funding: $656.4M
Astria Therapeutics discovers and develops innovative drugs for treating inflammatory conditions.
Astria Therapeutics discovers and develops innovative drugs for treating inflammatory conditions.
9
Country: USA | Funding: $397M
Evelo is pioneering therapies that modulate systemic immune response by acting on the gut-body network - monoclonal microbials. They have the potential to treat many diseases, including inflammatory disease, cancer, autoimmune disease, metabolic, neurobehavior and neuroinflammatory diseases.
Evelo is pioneering therapies that modulate systemic immune response by acting on the gut-body network - monoclonal microbials. They have the potential to treat many diseases, including inflammatory disease, cancer, autoimmune disease, metabolic, neurobehavior and neuroinflammatory diseases.
10
Country: France | Funding: $179.5M
HiFiBiO Therapeutics is biotherapeutics company mobilizing the human immune system to combat disease. We integrate deep-rooted biological expertise with our comprehensive single-cell profiling technologies to rapidly discover and advance a pipeline of antibody drugs to treat cancer and autoimmune disorders. We also aspire to benefit patients through open-innovation partnerships with industry and academia.
HiFiBiO Therapeutics is biotherapeutics company mobilizing the human immune system to combat disease. We integrate deep-rooted biological expertise with our comprehensive single-cell profiling technologies to rapidly discover and advance a pipeline of antibody drugs to treat cancer and autoimmune disorders. We also aspire to benefit patients through open-innovation partnerships with industry and academia.
11
Country: USA | Funding: $176M
Santa Ana Bio is a biotechnology company focusing on precision immunology for autoimmune and inflammatory diseases.
Santa Ana Bio is a biotechnology company focusing on precision immunology for autoimmune and inflammatory diseases.
12
Country: USA | Funding: $86.9M
Vaccinex is a biotechnology company engaged in the development of novel therapeutic antibodies for neurodegenerative disorders and oncology.
Vaccinex is a biotechnology company engaged in the development of novel therapeutic antibodies for neurodegenerative disorders and oncology.
13
Country: USA | Funding: $22.3M
Aqualung Therapeutics is developing a novel, anti-inflammatory monoclonal antibody strategy to treat serious unchecked inflammation.
Aqualung Therapeutics is developing a novel, anti-inflammatory monoclonal antibody strategy to treat serious unchecked inflammation.
★
See also:
